Stem cell treatment in Amyotrophic Lateral Sclerosis

Mazzini, Letizia; Mareschi, Katia; Ferrero, Ivana; Vassallo, Elena; Oliveri, Giuseppe; Nasuelli, Nicola; Oggioni, Gaia Donata; Testa, Lucia; Fagioli, Franca

doi:10.1016/j.jns.2007.05.016

Cited by 199 publications

(106 citation statements)

References 39 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These confirms and reassure the previous findings by other groups about the safety of the IT infusion of SCs [52,53,[68][69][70]72,77].…”

Section: Safetysupporting

confidence: 92%

See 1 more Smart Citation

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

“…These confirms and reassure the previous findings by other groups about the safety of the IT infusion of SCs [52,53,[68][69][70]72,77].…”

Section: Safetysupporting

confidence: 92%

“…Our results support the safety of the method and add unique information about the effectiveness of autologous stem cells to treat ALS supporting previous reports that described safety, feasibility and in some cases stop of the functional declination [52,53,[68][69][70]72,77].…”

Section: Alsfrs-rsupporting

confidence: 90%

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Ruiz-Navarro¹,

Kobinia²

2017

JSRT

View full text Add to dashboard Cite

“…To this point, human studies have reported common side effects of transient fevers, headaches, increased spasticity, mild sensory changes in the legs and sacral region, and neuropathic pain. [17][18][19][20][21][22] Catastrophic demyelinating encephalomyelitis, 23 spinal myoclonus, 24 and complications related to immunosuppression have also been reported. 17 There has been a report of donor-derived brainstem tumor following neural stem cell transplantation in a patient with ataxia telangiectasia.…”

Section: Discussionmentioning

confidence: 99%

Erratum: Inflammatory hypertrophic cauda equina following intrathecal neural stem cell injection

2013

Muscle and Nerve

View full text Add to dashboard Cite

Introduction: Potential benefit from stem cell treatments has more patients seeking treatment without understanding possible risks. Methods: We describe a woman who presented with progressive bilateral leg pain, numbness, and gait difficulties. A prior stroke, macular degeneration, osteoarthritis, and depression, led her to receive intrathecal neural stem cell therapy overseas 1 year before onset of symptoms. Results: Imaging showed marked enlargement of lumbosacral roots of the cauda equina, which was not seen before stem cell treatment. Electrodiagnostic studies confirmed chronic multiple lumbosacral radiculopathies. Biopsy of a lumbar dorsal sensory root showed myelinated fiber degeneration and loss, with endoneurial inflammation. The hypertrophic inflammatory cauda equina syndrome was potentially triggered by the prior intrathecal neural stem cell injection. Conclusions: Safety of intrathecal stem cell treatments is not regulated routinely in overseas stem cell facilities. We wish to bring this potential complication to the attention of health care providers. 48: 831-835, 2013 The potential benefit for stem cell therapy to repair, restore, replace, and regenerate damaged tissues has many patients with chronic neurological conditions excited about possible treatments. Research in this area continues to grow throughout the world. The U.S. National Institute of Health reports over 45 registered trials world-wide that relate to stem cell therapy and spinal cord injury alone. Muscle Nerve1 There is no way to know how many unregistered and uncontrolled treatments are offered in "notorious" stem cell clinics for chronic conditions that range from rejuvenation to cerebral palsy, stroke, Parkinson disease, traumatic brain and spinal cord injury, multiple sclerosis, and amyotrophic lateral sclerosis.2-5 Along with increased research, more and more patients are seeking stem cell therapy before the safety and efficacy of such treatments have been established. Some experts have concerns that the hope and expectations patients have for cures cannot be met. This may leave patients vulnerable to nonregulated providers of stem cell treatments that are potentially harmful. 3,6 Stem cells have 3 fundamental properties. First, they have a high proliferative potential. Second, they are capable of self-renewal. Third, they have the ability to differentiate into multiple cell types.These properties are what make stem cell therapy so attractive, especially in the setting of central nervous system injury, such as acute spinal cord injury, prior stroke, multiple sclerosis, and amyotrophic lateral sclerosis. However, these same properties, without a full understanding or control of their subsequent activities, are what potentially make stem cell therapy dangerous. Cells in a different environment may multiply, form tumors, or leave the site of origin and migrate somewhere else in the body. 4,5 In this case report, we postulate that intrathecal administration of neural stem cells may have induced inflammatory hypertroph...

show abstract

“…Bone marrow-derived MSCs are another source of therapeutic potential in ALS [74]. MSCs may exert neuroprotective effects via paracrine, or "bystander", mechanisms, such as the release of anti-inflammatory, anti apoptotic, and neurotrophic factors, and by influencing other cell types to take on a protective phenotype [109,110].…”

Section: Bone Marrow-derived Hematopoietic Progenitor Stem Cellsmentioning

confidence: 99%

“…A case in which an Ommaya reservoir was utilized for intraventricular delivery of bone marrow-derived MSCs reported no adverse events [72]. Consecutive phase I studies in Italy in which bone marrow was obtained from the iliac crest and expanded in vitro prior to direct surgical implantation of the cells into the dorsal spinal cord involved 9 patients initially [73,74], followed by an additional 10 patients [76], for a total of 19 patients [75]. In these studies, the procedure was well-tolerated and led to a slowed disease course in 6 patients; 4 of these patients were the youngest in the trials, and 2 subjects had a lower MN-predominant form of the disease.…”

Section: Bone Marrow-derived Hematopoietic Progenitor Stem Cellsmentioning

confidence: 99%

Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis

2015

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease of the motor neurons without a known cure. Based on the possibility of cellular neuroprotection and early preclinical results, stem cells have gained widespread enthusiasm as a potential treatment strategy. Preclinical models demonstrate a protective role of engrafted stem cells and provided the basis for human trials carried out using various types of stem cells, as well as a range of cell delivery methods. To date, no trial has demonstrated a clear therapeutic benefit; however, results remain encouraging and are the basis for ongoing studies. In addition, stem cell technology continues to improve, and induced pluripotent stem cells may offer additional therapeutic options in the future. Improved disease models and clinical trials will be essential in order to validate stem cells as a beneficial therapy.

show abstract

Stem cell treatment in Amyotrophic Lateral Sclerosis

Cited by 199 publications

References 39 publications

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Point-Of-Care Stem Cell Therapy (POCST): Multisite transplantation of autologous bone marrow-derived mononuclear cells in 85 patients with Amyotrophic Lateral Sclerosis improves survival

Erratum: Inflammatory hypertrophic cauda equina following intrathecal neural stem cell injection

Recent Advances and the Future of Stem Cell Therapies in Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About